Cancers

Article	Citations
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review	449
A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis	298
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer	243
The Landscape of Targeted Therapies in TNBC	224
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy	210
The CCL5/CCR5 Axis in Cancer Progression	203
Molecular Biology of Osteosarcoma	193
Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies	190
STING Agonists as Cancer Therapeutics	184
The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response	183
Organoid and Spheroid Tumor Models: Techniques and Applications	182
CA125 and Ovarian Cancer: A Comprehensive Review	174
Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment	171
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies	166
DNA Damage/Repair Management in Cancers	165
Green Chemistry Synthesis of Silver Nanoparticles and Their Potential Anticancer Effects	162
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer	155
The Warburg Effect 97 Years after Its Discovery	151
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer	151
Interleukin-1β and Cancer	147
The Role of Macrophages in Cancer Development and Therapy	146
A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies	146
Epidemiology of Glioblastoma Multiforme–Literature Review	145
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance	144
Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis	144

Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer	144
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors	138
The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities	137
Photodynamic Therapy: A Compendium of Latest Reviews	137
Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies	132
Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations	131
Novel Transfer Learning Approach for Medical Imaging with Limited Labeled Data	128
IL-12 Family Cytokines in Cancer and Immunotherapy	124
DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy	123
Cannabidiol (CBD) as a Promising Anti-Cancer Drug	123
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma	123
Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities	122
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance	122
Personalized Medicine: Recent Progress in Cancer Therapy	121
The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review	121
The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy	117
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis	114
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma	113
Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries	111
Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment	111
Three-Dimensional Culture System of Cancer Cells Combined with Biomaterials for Drug Screening	110
Warburg and Beyond: The Power of Mitochondrial Metabolism to Collaborate or Replace Fermentative Glycolysis in Cancer	109
Molecular Bases of Drug Resistance in Hepatocellular Carcinoma	109
Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis	108
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer	107
FLASH Proton Pencil Beam Scanning Irradiation Minimizes Radiation-Induced Leg Contracture and Skin Toxicity in Mice	106
Application of Artificial Intelligence Technology in Oncology: Towards the Establishment of Precision Medicine	105
The Role of p53 Signaling in Colorectal Cancer	105
Targeting Multiple Signaling Pathways in Cancer: The Rutin Therapeutic Approach	105
Flavonoids in Cancer Metastasis	105
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma	103
Non-Invasive Biomarkers for Early Detection of Breast Cancer	103
Extracellular Glutathione Peroxidase GPx3 and Its Role in Cancer	103
A Review of Circulating Tumour Cell Enrichment Technologies	102
Carbon Ion Radiobiology	102
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives	102
Tumor-Associated Macrophage Status in Cancer Treatment	101
Epigenetic Associations between lncRNA/circRNA and miRNA in Hepatocellular Carcinoma	100
The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment	99
Gold Nanoparticles as a Potent Radiosensitizer: A Transdisciplinary Approach from Physics to Patient	99
The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis	99
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression	98
Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)	98
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer	98
The Role of Probiotics in Cancer Prevention	97
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II	97
The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC)	95
The Role of Cancer-Associated Fibroblasts in Tumor Progression	95
RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field	95
Chemotherapy Side-Effects: Not All DNA Damage Is Equal	94

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives	94
Mechanisms of Taxane Resistance	92
Metabolic Heterogeneity of Cancer Cells: An Interplay between HIF-1, GLUTs, and AMPK	92
Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death	90
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives	90
Impact of the COVID-19 Pandemic on Cancer Diagnoses in General and Specialized Practices in Germany	90
Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma	89
Mechanisms of Long Non-Coding RNAs in Cancers and Their Dynamic Regulations	89
Immune Escape Mechanisms in Non Small Cell Lung Cancer	89
Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy	89
Arginine Signaling and Cancer Metabolism	88
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy	88
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update	88
Neutrophil Extracellular Traps (NETs) in Cancer Invasion, Evasion and Metastasis	87
Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment	87
Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity	87
Emerging Therapies for Hepatocellular Carcinoma (HCC)	87
Oral–Gut Microbiome Axis in Gastrointestinal Disease and Cancer	86
Stimuli-Responsive Hydrogels for Cancer Treatment: The Role of pH, Light, Ionic Strength and Magnetic Field	86
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment	86
New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines	85
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy	85
Light Technology for Efficient and Effective Photodynamic Therapy: A Critical Review	85
Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets	85
Progress in Clinical Trials of Photodynamic Therapy for Solid Tumors and the Role of Nanomedicine	84
MicroRNA Therapeutics in Cancer: Current Advances and Challenges	84
Mechanisms of Resistance to KRASG12C Inhibitors	83
Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Ration	83
Diffusion-Weighted Imaging in Oncology: An Update	83
Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease	82
Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy	82
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy	82
Cancer and Aging: Two Tightly Interconnected Biological Processes	81
Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions	81
Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting	81
Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study	81
Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments	81
Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications	81
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter	81
Immune Resistance in Lung Adenocarcinoma	80
Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation	80
Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion	80
Cyclic Hypoxia: An Update on Its Characteristics, Methods to Measure It and Biological Implications in Cancer	80
Transfer Learning in Breast Cancer Diagnoses via Ultrasound Imaging	80
BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions	80
Neutrophil Extracellular Traps (NETs) Promote Pro-Metastatic Phenotype in Human Breast Cancer Cells through Epithelial–Mesenchymal Transition	79
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer	79
Glucose Transporters as a Target for Anticancer Therapy	78
Recent Development of Gold Nanoparticles as Contrast Agents for Cancer Diagnosis	77
A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy	77
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management	77
The Exciting New Field of HER2-Low Breast Cancer Treatment	77
Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis	77
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far	77
3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs	76
Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment	76
The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis	76
Impact of the Tumor Microenvironment on Tumor Heterogeneity and Consequences for Cancer Cell Plasticity and Stemness	76
Tunneling Nanotubes and Tumor Microtubes in Cancer	76
Evolution of the Experimental Models of Cholangiocarcinoma	75
Carbon Dots as Promising Tools for Cancer Diagnosis and Therapy	75
Cancer Stem Cells—Key Players in Tumor Relapse	75
The Role of Artificial Intelligence in Early Cancer Diagnosis	74
Role of MSC in the Tumor Microenvironment	74
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations	74
Radioresistance in Glioblastoma and the Development of Radiosensitizers	74
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy	73
EMT-Associated Heterogeneity in Circulating Tumor Cells: Sticky Friends on the Road to Metastasis	73
Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy	73
Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches	73
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review	73
Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review	73
PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy	73
Neuroprotection of Radiosensitive Juvenile Mice by Ultra-High Dose Rate FLASH Irradiation	73
Cancer-Associated Fibroblasts: Understanding Their Heterogeneity	73
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer	73
Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality	72
Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential	72
The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy	72
Indolepropionic Acid, a Metabolite of the Microbiome, Has Cytostatic Properties in Breast Cancer by Activating AHR and PXR Receptors and Inducing Oxidative Stress	72

Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment	72
Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome	72
Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment	72
Friend or Foe: S100 Proteins in Cancer	72
Promising Applications of Tumor Spheroids and Organoids for Personalized Medicine	72
Transcription Factors in Cancer Development and Therapy	71
Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021	71
Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies	70
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview	70
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer	70
Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment	70
Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology	70
Plasma-Treated Solutions (PTS) in Cancer Therapy	70
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling	70
JAK-STAT Signalling Pathway in Cancer	70
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions	70
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges	69
Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma	69
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer	69
Past, Present and Future of Oncolytic Reovirus	69
Merkel Cell Polyomavirus and Merkel Cell Carcinoma	69
Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials	69
Multiparametric MRI for Prostate Cancer Characterization: Combined Use of Radiomics Model with PI-RADS and Clinical Parameters	69
Radiomics of Liver Metastases: A Systematic Review	69
RNA-Binding Proteins in Cancer: Functional and Therapeutic Perspectives	69
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival	69
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer	69
Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics	69
MMP9: A Tough Target for Targeted Therapy for Cancer	68
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials	68
Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study	68
Mechanisms of Resistance to Conventional Therapies for Osteosarcoma	68
Linking Obesity with Colorectal Cancer: Epidemiology and Mechanistic Insights	68
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives	68
Sex and Gender Disparities in Melanoma	67
Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance	67
FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?	67
Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence	66
Trends in Research on Exosomes in Cancer Progression and Anticancer Therapy	66
Carotenoids in Cancer Apoptosis—The Road from Bench to Bedside and Back	66
Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance	66
The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions	66
The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer	66
Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy	66
Perspectives on the Role of Isoliquiritigenin in Cancer	66
How and Why Are Cancers Acidic? Carbonic Anhydrase IX and the Homeostatic Control of Tumour Extracellular pH	66
The Dynamic Relationship of Breast Cancer Cells and Fibroblasts in Fibronectin Accumulation at Primary and Metastatic Tumor Sites	66
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma	66
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy	66
Long Non-Coding RNA HOTAIR in Breast Cancer Therapy	66
Extracellular Vesicles as Biomarkers in Cancer Immunotherapy	65
Pathology and Classification of SCLC	65
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice	65
The New Era of Immunotherapy in Gastric Cancer	65
Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets	65
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?	65
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy	65
Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview	65
The Functional Role of Extracellular Matrix Proteins in Cancer	65
Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers	64
Mechanosensitive Piezo Channels in Cancer: Focus on altered Calcium Signaling in Cancer Cells and in Tumor Progression	64
Non-Coding RNAs as Mediators of Epigenetic Changes in Malignancies	64
Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update	64
Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis	64
Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin	64
Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer	63
Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?	63
Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies	63
Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis	63
Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations	63
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?	63
An Updated Review on Head and Neck Cancer Treatment with Radiation Therapy	62
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies	62
Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers	62
Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis	62
The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis	62
MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review	62
Tumor Microenvironment as a Regulator of Radiation Therapy: New Insights into Stromal-Mediated Radioresistance	62
New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis	61
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors	61
O-GlcNAcylation and O-GlcNAc Cycling Regulate Gene Transcription: Emerging Roles in Cancer	61
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers	60
Hypoalbuminemia Reflects Nutritional Risk, Body Composition and Systemic Inflammation and Is Independently Associated with Survival in Patients with Colorectal Cancer	60
Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?	60
The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers	60
LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia	60
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer	60
Transcriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages	60
Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis	60
The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma	60
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer	59
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives	59
The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy	59
The Role of CCL21/CCR7 Chemokine Axis in Breast Cancer Progression	59
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas	59